Axsome Therapeutics Files 8-K for 'Other Events' & Financial Exhibits

Ticker: AXSM · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1579428

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, regulatory-filing, general-update

TL;DR

**AXSM filed a standard 8-K for general updates and exhibits, nothing major.**

AI Summary

Axsome Therapeutics, Inc. filed an 8-K on January 8, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing, under SEC File Number 001-37635, indicates that the company is not an emerging growth company and its Common Stock (AXSM) is registered on the Nasdaq Global Market. For investors, this filing signals standard operational updates and confirms the company's established status, which can be reassuring regarding its regulatory compliance and market presence.

Why It Matters

This filing provides routine updates on Axsome Therapeutics' corporate status and confirms its listing on the Nasdaq Global Market, offering transparency to investors.

Risk Assessment

Risk Level: low — This 8-K filing is for general information and does not disclose any specific events that would materially impact the company's risk profile.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material changes, and would continue to monitor for more substantive news or financial reports.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Axsome Therapeutics, Inc.'s 8-K filing dated January 08, 2024?

The 8-K filing by Axsome Therapeutics, Inc. on January 08, 2024, is categorized under 'Other Events' and 'Financial Statements and Exhibits,' indicating it provides general updates and includes any required financial documents or exhibits.

Is Axsome Therapeutics, Inc. considered an 'emerging growth company' according to this filing?

No, the filing explicitly indicates with an unchecked box that Axsome Therapeutics, Inc. is not an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

On which stock exchange is Axsome Therapeutics, Inc.'s Common Stock registered?

Axsome Therapeutics, Inc.'s Common Stock, with the trading symbol AXSM, is registered on the Nasdaq Global Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.

What is the business address and phone number for Axsome Therapeutics, Inc. as listed in the filing?

The business address for Axsome Therapeutics, Inc. is One World Trade Center, 22nd Floor, New York, New York, 10007, and their telephone number is (212) 332-3241.

What is the Central Index Key (CIK) for Axsome Therapeutics, Inc.?

The Central Index Key (CIK) for Axsome Therapeutics, Inc. is 0001579428, as found in the 'COMPANY DATA' section of the filing.

Filing Stats: 416 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-01-08 07:10:07

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 8, 2024, the Company updated its corporate presentation and posted such corporate presentation to the Company’s website. The updated corporate presentation is filed as Exhibit 99.1 hereto and incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: January 8, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing